Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Blackstone Inc (BX) vs Cassava Sciences Inc (FLNA) Price & Performance

Blackstone IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Blackstone Inc vs Cassava Sciences Inc — how do they compare? Blackstone Inc trades at $126.79 (market cap $152.15B), while Cassava Sciences Inc trades at $1.11 (market cap $52.66M). The key difference: Blackstone Inc is far larger — about 2889.3× Cassava Sciences Inc's market cap, and Blackstone Inc pays a 3.99% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

BXFLNA
Market Cap
$152.15B$52.66M
Sector
FinancialsHealth
52-Week High
$188.68$4.64
52-Week Low
$102.12$1.09
Dividend Yield
3.99%
Enterprise Value
-$33.92M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Blackstone Inc

Blackstone (BX) trades at $122.06, down 0.83% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 24.27% net income margin highlight robust profitability, while a $5.34 billion AI infrastructure deal with Williams underscores strategic growth. The stock faces resistance near $123 with support at $121.

Outlook remains positive given consistent earnings outperformance and institutional bullishness, though valuation multiples like a P/E of 31.29 pose risks if growth slows. Key opportunities include AI-driven investments, while macroeconomic volatility and high leverage are concerns.

Cassava Sciences Inc

FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.

Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Blackstone Inc

Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.

Read more on BX

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA